Medical Supply Sanctions Act of 2025
- Bill Number
- H.R. 4762
- Origin Chamber
- House
- Congress
- 119th Congress, Session 1
- Policy Area
- International Affairs
- Status
- Introduced
- Latest Action
- 2025-07-25: Referred to the House Committee on Foreign Affairs.
- Last Updated
- 2025-10-09T03:26:18Z
AI-Generated Summary
Purpose
The Medical Supply Sanctions Act of 2025 aims to impose economic sanctions on the Russian Federation by banning the export of certain medical goods, specifically drugs and prosthetics, from the United States. This measure is intended as a response to Russia's military actions in Ukraine, limiting access to U.S.-made medical supplies that could support Russian healthcare or military efforts.
Key Provisions
- Export Prohibition: The President must prohibit the export of any drug or prosthetic to Russia, overriding any conflicting laws.
- Definitions:
- Drug: Refers to any substance approved by the Food and Drug Administration (FDA) for use in treating or preventing diseases (as defined under the Federal Food, Drug, and Cosmetic Act), including any of its components.
- Prosthetic: A medical device that replaces a missing body part or enhances the function of an existing one, authorized for sale by the FDA, including any parts, components, or accessories.
- Sunset Clause: The ban ends when the Secretary of State certifies to Congress that Russia has stopped its military operations in Ukraine and withdrawn all forces from the country.
Significant Changes to Existing Law
- This bill introduces a blanket prohibition on exporting FDA-approved drugs and prosthetics to Russia, which overrides prior export regulations or licensing requirements under laws like the Export Administration Regulations or the Arms Export Control Act.
- It expands sanctions by targeting civilian medical goods, potentially closing loopholes that previously allowed such exports under humanitarian exceptions.
Potential Impacts
- Government Agencies: The President and Department of State gain enforcement responsibilities, including monitoring compliance and issuing the sunset certification. Agencies like the FDA and Department of Commerce may need to adjust export licensing processes to enforce the ban.
- Citizens: U.S. patients and healthcare providers are unaffected domestically, but Russian civilians could face shortages of essential U.S.-sourced medications and prosthetic devices, potentially harming public health in Russia.
- International Relations: This escalates U.S. sanctions against Russia, straining diplomatic ties and possibly prompting retaliatory measures. It could influence allied nations' policies on medical exports to Russia and affect global supply chains for pharmaceuticals.
Main Stakeholders Affected
- U.S. Exporters: Pharmaceutical companies, medical device manufacturers (e.g., producers of prosthetics like artificial limbs), and their suppliers, who will lose access to the Russian market and face compliance costs.
- Russian Entities: Healthcare providers, hospitals, and civilians in Russia reliant on imported U.S. drugs and prosthetics for treatment of illnesses or injuries.
- U.S. Government: Executive branch agencies (e.g., State Department, FDA) responsible for implementation and oversight.
- International Actors: Ukraine (potential beneficiary through reduced Russian military support) and global trade partners affected by disrupted medical supply chains.
Notable Legal, Constitutional, or Political Implications
- Legal: The "notwithstanding" clause ensures the ban supersedes other federal laws, providing clear authority but potentially leading to legal challenges from affected businesses seeking export waivers. Enforcement relies on existing presidential powers under the International Emergency Economic Powers Act (IEEPA), a common framework for sanctions.
- Constitutional: Congress delegates certification authority to the executive branch, aligning with separation of powers precedents for foreign policy, though it maintains congressional oversight via the sunset requirement.
- Political: As a targeted sanction, it signals strong U.S. opposition to Russia's invasion of Ukraine without broader military involvement, but it risks criticism for impacting civilian health, raising humanitarian concerns in international forums like the United Nations.
This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.
Sponsor
Rep. Luttrell, Morgan [R-TX-8]
Recent Actions
- 2025-07-25: Referred to the House Committee on Foreign Affairs.
- 2025-07-25: Introduced in House
- 2025-07-25: Introduced in House
Bill Versions
- Medical Supply Sanctions Act of 2025 — issued 2025-07-25 — PDF (2 pages)